The Food and Drug Administration has granted Cytogen of Princeton,NJ, a license to market its ProstaScint monoclonal antibody agentfor prostate cancer imaging. Cytogen plans to have ProstaScinton the market by early next year. ProstaScint is licensed
The Food and Drug Administration has granted Cytogen of Princeton,NJ, a license to market its ProstaScint monoclonal antibody agentfor prostate cancer imaging. Cytogen plans to have ProstaScinton the market by early next year.
ProstaScint is licensed for two indications: to image newlydiagnosed patients whose biopsy-proven prostate cancer is at highrisk of metastasizing to pelvic lymph nodes, and for post-prostatectomypatients in whom there is a suspicion of cancer recurrence.
Cytogen has licensed ProstaScint rights for the urologicalmarket to C.R. Bard's urologic division, while Cytogen will retainrights to the medical imaging market (SCAN 8/28/96).
Cytogen is hoping that ProstaScint will prove to be more successfulthan its OncoScint CR/OV product for imaging colorectal and ovariancancer. The company plans to support ProstaScint through its Partnersin Excellence program, which is designed to help ensure that nuclearmedicine physicians are reading monoclonal antibody scans correctly(SCAN 9/25/96).
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.